Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7306 to 7320 of 8314 results

  1. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued Reference number: GID-NG10395

    NICE guideline
    Discontinued

  2. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

    NICE guideline
    Discontinued

  3. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

    Antimicrobial prescribing guideline
    Discontinued

  4. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  5. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  6. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

    Antimicrobial prescribing guideline
    Discontinued

  7. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued Reference number: GID-TA10933

    Technology appraisal guidance
    Discontinued

  9. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  10. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  12. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  13. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  14. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  15. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    Discontinued Reference number: GID-TA10728

    Technology appraisal guidance
    Discontinued